Cargando…

PARP is activated in human asthma and its inhibition by olaparib blocks house dust mite-induced disease in mice

Our laboratory established a role for poly(ADP-ribose)polymerase (PARP) in asthma. To increase the clinical significance of our studies, it is imperative to demonstrate that PARP is actually activated in human asthma, to examine whether a PARP inhibitor approved for human testing such as olaparib bl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghonim, Mohamed A., Pyakurel, Kusma, Ibba, Salome V., Wang, Jeffrey, Rodriguez, Paulo, Al-Khami, Amir A., Lammi, Matthew R., Kim, Hogyoung, Zea, Arnold H., Davis, Christian, Okpechi, Samuel, Wyczechowska, Dorota, Al-Ghareeb, Kamel, Mansy, Moselhy S., Ochoa, Augusto, Naura, Amarjit S., Boulares, A. Hamid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2015
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4613510/ https://www.ncbi.nlm.nih.gov/pubmed/26205779 http://dx.doi.org/10.1042/CS20150122

Ejemplares similares

PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function
por: Ghonim, Mohamed A, et al.
Publicado: (2015)

Potential of Inducible Nitric Oxide Synthase as a Therapeutic Target for Allergen-Induced Airway Hyperresponsiveness: A Critical Connection to Nitric Oxide Levels and PARP Activity
por: Ibba, Salome' V., et al.
Publicado: (2016)

PARP-1 Is Critical for Recruitment of Dendritic Cells to the Lung in a Mouse Model of Asthma but Dispensable for Their Differentiation and Function
por: Echeverri Tirado, Laura C., et al.
Publicado: (2019)

Sulfated non-anticoagulant heparin blocks Th2-induced asthma by modulating the IL-4/signal transducer and activator of transcription 6/Janus kinase 1 pathway
por: Ghonim, Mohamed A., et al.
Publicado: (2018)

Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer
por: Ghonim, Mohamed A, et al.
Publicado: (2021)

Promotion of a synthetic degradation of activated STAT6 by PARP-1 inhibition: roles of poly(ADP-ribosyl)ation, calpains and autophagy
por: Wang, Jeffrey, et al.
Publicado: (2022)

Correction: ApoE deficiency promotes colon inflammation and enhances the inflammatory potential of oxidized-LDL and TNF-α in primary colon epithelial cells
por: El-Bahrawy, Ali H., et al.
Publicado: (2016)

ApoE deficiency promotes colon inflammation and enhances the inflammatory potential of oxidized-LDL and TNF-α in primary colon epithelial cells
por: El-Bahrawy, Ali H., et al.
Publicado: (2016)

HIGH FAT DIET INDUCES LUNG REMODELING IN APOE DEFICIENT MICE: AN ASSOCIATION WITH AN INCREASE IN CIRCULATORY AND LUNG INFLAMMATORY FACTORS
por: Naura, Amarjit S., et al.
Publicado: (2009)

Protective Effects of PARP-1 Knockout on Dyslipidemia-Induced Autonomic and Vascular Dysfunction in ApoE(−/−) Mice: Effects on eNOS and Oxidative Stress
por: Hans, Chetan P., et al.
Publicado: (2009)

PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation
por: Mao, Yize, et al.
Publicado: (2018)

Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
por: Osoegawa, Atsushi, et al.
Publicado: (2017)

The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2015)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

PET Imaging of PARP Expression Using (18)F-Olaparib
por: Wilson, Thomas C., et al.
Publicado: (2019)

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib()
por: Wang, Chen, et al.
Publicado: (2017)

Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
por: Ordóñez, José Luis, et al.
Publicado: (2017)

Olaparib‐Based Photoaffinity Probes for PARP‐1 Detection in Living Cells
por: Voorneveld, Jim, et al.
Publicado: (2020)

PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells
por: Liu, Chuan, et al.
Publicado: (2020)

ICAD Deficiency in Human Colon Cancer and Predisposition to Colon Tumorigenesis: Linkage to Apoptosis Resistance and Genomic Instability
por: Errami, Youssef, et al.
Publicado: (2013)

An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma
por: Nile, Donna L., et al.
Publicado: (2016)

The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma
por: Park, Hye Jeong, et al.
Publicado: (2018)

PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation
por: Kageyama, Shun-ichiro, et al.
Publicado: (2020)

Recurrent Cervical Cancer Treated Successfully with Single-Agent PARP-Inhibitor, Olaparib
por: Gross, Maya, et al.
Publicado: (2022)

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
por: Daemen, Anneleen, et al.
Publicado: (2012)

Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer
por: Qin, Hongyu, et al.
Publicado: (2023)

PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors
por: Perini, Valentina, et al.
Publicado: (2020)

Aldose Reductase Inhibition Prevents Allergic Airway Remodeling through PI3K/AKT/GSK3β Pathway in Mice
por: Yadav, Umesh C. S., et al.
Publicado: (2013)

Poly(ADP-ribose) polymerase as a novel regulator of 17β-estradiol-induced cell growth through a control of the estrogen receptor/IGF-1 receptor/PDZK1 axis
por: Kim, Hogyoung, et al.
Publicado: (2015)

The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions
por: Orta, Manuel Luis, et al.
Publicado: (2014)

JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib
por: YANG, XUELI, et al.
Publicado: (2015)

PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
por: Yang, Xiao-Dong, et al.
Publicado: (2021)

PARP inhibitor olaparib enhances the efficacy of radiotherapy on XRCC2-deficient colorectal cancer cells
por: Qin, Changjiang, et al.
Publicado: (2022)

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
por: Bonciarelli, Stefano, et al.
Publicado: (2023)

Clinical utilization of olaparib, a PARP inhibitor, in BRCA1-mutant metastatic acral melanoma
por: Jiang, Ruixin, et al.
Publicado: (2022)

Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
por: de Haan, R., et al.
Publicado: (2019)

Effects of the PARP Inhibitor Olaparib on the Response of Human Peripheral Blood Leukocytes to Bacterial Challenge or Oxidative Stress
por: Santos, Sidneia Sousa, et al.
Publicado: (2022)

Poly(ADP-Ribose)Polymerase-1 in Lung Inflammatory Disorders: A Review
por: Sethi, Gurupreet S., et al.
Publicado: (2017)

PARP-1/2 Inhibitor Olaparib Prevents or Partially Reverts EMT Induced by TGF-β in NMuMG Cells
por: Schacke, Michelle, et al.
Publicado: (2019)

The PARP-1 inhibitor Olaparib suppresses BRCA1 protein levels, increases apoptosis and causes radiation hypersensitivity in BRCA1(+/-) lymphoblastoid cells
por: Bourton, Emma C., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_es86lvo7tjkomn9l3e6i9c69dv